Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | FDPS | P14324 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5243909 | 0.83 | FDPS (0.42) | CA12CA1FDPSCA2 | |
| SCHEMBL7927834 | 0.76 | MMP1 (0.38) | MMP1MMP2MMP3MMP8CA12 | |
| SCHEMBL11195464 | 0.72 | MMP1 (0.34) | MMP1MMP2MMP3MMP8CA12 | |
| SCHEMBL316766 | 0.71 | — | — | |
| SCHEMBL172366 | 0.70 | MMP1 (0.33) | MMP1MMP2MMP3MMP8CA12 | |
| SCHEMBL13178779 | 0.70 | MMP1 (0.33) | MMP1MMP2MMP3MMP8CA12 | |
| SCHEMBL3312355 | 0.70 | MMP1 (0.33) | MMP1MMP2MMP3MMP8CA12 | |
| SCHEMBL363491 | 0.70 | TSHR (0.33) | MMP1MMP2MMP3MMP8CA12 | |
| SCHEMBL27390123 | 0.70 | MMP1 (0.34) | MMP1MMP2MMP3MMP8CA12 | |
| SCHEMBL865548 | 0.69 | MMP1 (0.36) | MMP1MMP2MMP3MMP8CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674121-B2 | Process for the production of benzofurans | SANOFI (FR) | 2014-03-18 | — | — | US | disclosed |
| EP-2435398-B1 | PROCESS FOR THE PRODUCTION OF BENZOFURANS | SANOFI SA (FR) | 2014-01-22 | — | — | EP | disclosed |
| WO-2013079866-A1 | METHOD FOR PREPARING 5-AMINO-BENZOYL-BENZOFURAN DERIVATIVES | SANOFI (FR) | 2013-06-06 | — | — | WO | disclosed |
| EP-2542544-A1 | KETOBENZOFURAN DERIVATIVES, METHOD FOR SYNTHESISING SAME, AND INTERMEDIATES | SANOFI (FR) | 2013-01-09 | — | — | EP | disclosed |
| US-20120065411-A1 | PROCESS FOR THE PRODUCTION OF BENZOFURANS | SANOFI (FR) | 2012-03-15 | — | — | US | disclosed |
| WO-2010136500-A1 | PROCESS FOR THE PRODUCTION OF BENZOFURANS | SANOFI-AVENTIS (FR) | 2010-12-02 | — | — | WO | disclosed |
| EP-0818512-B1 | Quinoline derivative and use of same | MITSUI CHEMICALS INC (JP) | 2002-10-02 | — | — | EP | disclosed |
| US-6407242-B1 | REACTING A PHTHALIMIDE COMPOUND WITH A QUINOLINE COMPOUND;ELECTROLUMINESCENCE | MITSUI CHEMICALS, INC. (JP) | 2002-06-18 | — | — | US | disclosed |
| US-6132640-A | ZINC COMPLEXES OF QUINOLINE | MITSUI CHEMICALS, INC. (JP) | 2000-10-17 | — | — | US | disclosed |
| EP-0818512-A1 | Quinoline derivative and use of same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1998-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065411-A1 | PROCESS FOR THE PRODUCTION OF BENZOFURANS | CYP2F1, CYP2B6, CYP4F2 | MMP1 4395/4885MMP2 3478/4885MMP3 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.